Community-acquired pneumonia and skin infections: does ceftaroline improve outcomes?

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Results suggest ceftaroline is a safe and effective therapeutic alternative for patients with community-acquired pneumonia (CAP) or complicated skin and skin structure infections (cSSSI), but it should currently be reserved as an alternative rather than first-line option.

Why this matters

  • Early, widespread use of ceftaroline may promote resistance, and current evidence calls for more conservative conclusions regarding its place in therapy.

Study design

  • Systematic review and meta-analysis comparing efficacy and safety of ceftaroline vs standard antibiotic regimens for CAP and cSSSIs.
  • Funding: None.

Key results

  • 3 randomized controlled trials per indication.
  • Comparator agents: Ceftriaxone in CAP and vancomycin plus aztreonam in cSSSI.
  • In CAP (n=2011), ceftaroline was statistically significantly more efficacious for clinical cure compared to ceftriaxone (risk ratio [RR], 1.11).
  • In cSSSI (n=1496), no statistically significant difference in clinical cure between ceftaroline and comparator regimen (RR, 1.01).
  • No statistically significant difference in mortality for either indication.
  • No major findings for safety outcomes.

Limitations

  • Risk for industry influence was high among studies included in meta-analysis.
  • Possible selective outcome reporting bias.